Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Weingold

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Journal of Diabetes and Its Complications|October 18, 2023
Shifts in KDIGO CKD risk groups with empagliflozin: Kidney-protection from SGLT2 inhibition across the spectrum of riskRobert Weingold, Bernard Zinman, Michaela Mattheus, et al.
Journal of Diabetes and Its Complications|February 12, 2026
Finerenone increases the likelihood of improved KDIGO risk category in patients with CKD and type 2 diabetes: An analysis from FIDELITYRobert Weingold, Gerasimos Filippatos, Stefan D Anker, et al.
Nature Communications|June 9, 2017
Spaser as a biological probeEkaterina I Galanzha, Robert Weingold, Dmitry A Nedosekin, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Journal of Diabetes and Its Complications|October 18, 2023
Shifts in KDIGO CKD risk groups with empagliflozin: Kidney-protection from SGLT2 inhibition across the spectrum of riskRobert Weingold, Bernard Zinman, Michaela Mattheus, et al.
Journal of Diabetes and Its Complications|February 12, 2026
Finerenone increases the likelihood of improved KDIGO risk category in patients with CKD and type 2 diabetes: An analysis from FIDELITYRobert Weingold, Gerasimos Filippatos, Stefan D Anker, et al.
Nature Communications|June 9, 2017
Spaser as a biological probeEkaterina I Galanzha, Robert Weingold, Dmitry A Nedosekin, et al.
Pageof 1